Genome-wide pharmacogenetics of antidepressant response in the GENDEP project
|Published in||American Journal of Psychiatry. 2010, vol. 167, no. 5, p. 555-564|
|Abstract||OBJECTIVE: The purpose of this study was to identify genetic variants underlying the considerable individual differences in response to antidepressant treatment. The authors performed a genome-wide association analysis of improvement of depression severity with two antidepressant drugs. METHOD: High-quality Illumina Human610-quad chip genotyping data were available for 706 unrelated participants of European ancestry treated for major depression with escitalopram (N=394) or nortriptyline (N=312) over a 12-week period in the Genome-Based Therapeutic Drugs for Depression (GENDEP) project, a partially randomized open-label pharmacogenetic trial. RESULTS: Single nucleotide polymorphisms in two intergenic regions containing copy number variants on chromosomes 1 and 10 were associated with the outcome of treatment with escitalopram or nortriptyline at suggestive levels of significance and with a high posterior likelihood of true association. Drug-specific analyses revealed a genome-wide significant association between marker rs2500535 in the uronyl 2-sulphotransferase gene and response to nortriptyline. Response to escitalopram was best predicted by a marker in the interleukin-11 (IL11) gene. A set of 72 a priori-selected candidate genes did not show pharmacogenetic associations above a chance level, but an association with response to escitalopram was detected in the interleukin-6 gene, which is a close homologue of IL11. CONCLUSIONS: While limited statistical power means that a number of true associations may have been missed, these results suggest that efficacy of antidepressants may be predicted by genetic markers other than traditional candidates. Genome-wide studies, if properly replicated, may thus be important steps in the elucidation of the genetic basis of pharmacological response.|
|Keywords||Antidepressive Agents/*therapeutic use — Antidepressive Agents, Second-Generation/therapeutic use — Citalopram/therapeutic use — Depressive Disorder/*drug therapy/genetics — Depressive Disorder, Major/drug therapy/genetics — *Genome-Wide Association Study — Genotype — Humans — Interleukin-11/genetics — Interleukin-6/genetics — Nortriptyline/therapeutic use — Oligonucleotide Array Sequence Analysis — Pharmacogenetics/methods — Phenotype — Polymorphism, Single Nucleotide/genetics — Psychiatric Status Rating Scales — Sulfotransferases/genetics — Treatment Outcome|
This document has no fulltext available yet, but you can contact its author by using the form below.
|UHER, Rudolf et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. In: American Journal of Psychiatry, 2010, vol. 167, n° 5, p. 555-564. doi: 10.1176/appi.ajp.2009.09070932 https://archive-ouverte.unige.ch/unige:20578|